Novartis AG (SWX:NOVNEE)

Market Cap	241.34B +27.8%
Revenue (ttm)	44.94B +9.6%
Net Income	11.09B +17.1%
EPS	5.67 +21.8%
Shares Out	n/a
PE Ratio	21.76
Forward PE	18.25
Dividend	n/a
Ex-Dividend Date	n/a

Volume	91,291
Average Volume	175,565
Open	127.14
Previous Close	126.80
Day's Range	126.34 - 127.28
52-Week Range	81.55 - 129.58
Beta	0.49
RSI	72.65
Earnings Date	Feb 4, 2026

About Novartis AG

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1996
• Employees: 75,267
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: NOVNEE

Financial Performance

In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.

Financial numbers in USD